Bristol-Myers Squibb Company (NYSE:BMY) Q3 2024 Results Conference Call October 31, 2024 8:00 AM ET
Company Participants
Chuck Triano - Senior Vice President, Investor Relations
Chris Boerner - Board Chair & Chief Executive Officer
David Elkins - Chief Financial Officer
Adam Lenkowsky - Chief Commercialization Officer
Samit Hirawat - Chief Medical Officer & Head of Global Drug Development
Conference Call Participants
Evan Seigerman - BMO Capital Markets
Chris Shibutani - Goldman Sachs
Chris Schott - JPMorgan
Luisa Hector - Berenberg
Geoff Meacham - Citibank
Carter Gould - Barclays
Trung Huynh - UBS
Steve Scala - Cowen
Courtney Breen - Bernstein
Seamus Fernandez - Guggenheim Securities
Matt Phipps - William Blair
David Risinger - Leerink Partners
Akash Tewari - Jefferies
James Shin - Deutsche Bank
Olivia Brayer - Cantor
Sean McCutchen - Raymond James
Srikripa Devarakonda - Truist Securities
Operator
Good day, and welcome to the Bristol-Myers Squibb Third Quarter 2024 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
I would now like to turn the conference over to Mr. Chuck Triano, Senior Vice President of Investor Relations. Please go ahead, sir.
Chuck Triano
Thank you, and good morning, everyone. I'm happy to be here at Bristol-Myers Squibb, and we appreciate you joining our third quarter 2024 earnings call.
Joining me this morning with prepared remarks are Chris Boerner, our Board Chair and Chief Executive Officer; and David Elkins, our Chief Financial Officer. Also participating in today's call are Adam Lenkowsky, our Chief Commercialization Officer; and Samit Hirawat, our Chief Medical Officer and Head of Global Drug Development.
Earlier this morning, we posted our quarterly slide presentation to bms.com that you can use to follow along with Chris and David's remarks. Before we get started, I'll remind everybody that during this call we will make statements about the company's future plans and prospects that constitute forward-looking statements.
Actual results may differ materially from those indicated by those forward-looking statements as a result of various important factors, including those discussed in the company's SEC filings. These forward-looking statements represent our estimates as of today and should not be relied upon as representing our estimates as of any future date and we specifically disclaim any obligation to update forward-looking statements, even if our estimates change.
We'll also focus our comments on our non-GAAP financial measures, which are adjusted to exclude certain specified items. Reconciliations of certain non-GAAP financial measures to the most comparable GAAP measures are available at bms.com.